Viatris (VTRS)
NASDAQ: VTRS · Pharmaceuticals · Canonsburg, PA
Our rating: Neutral
Neutral reaffirmed at $19.91, moderate conviction, November 6, 2026.
Breaks if: The Neutral call moves Positive if reported free cash flow for any trailing twelve-month period clears $2.1B while year-over-year revenue decline narrows to 1% or less, indicating the erosion is plateauing and cash conversion is strengthening. It moves Cautious if trailing twelve-month free cash flow falls below $1.4B — a drop of roughly one quarter from current levels — signaling that revenue attrition is now flowing through to the cash line and the core yield thesis has cracked.
Key figures
| Market value | $22.5B |
|---|---|
| Revenue, last 12 months | $14.7B |
| Net income, last 12 months | n/a |
| Free cash flow, last 12 months | $2.1B |
| Price to earnings | n/a |
| Free cash flow yield | 9.4% |
| Dividend yield | 2.4% |
| Operating margin | −0.0% |
| Return on equity | n/a |
| Beta to the S&P 500 | 0.72 |
| Volatility, annualized | 33.1% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $3.7B | −0.3% | $-0.28 | $814M |
| June 30, 2026 | $3.7B | 5.0% | $-0.10 | $329M |
| March 31, 2026 | $3.5B | 8.2% | $0.15 | $348M |
| December 31, 2025 | $3.7B | 5.0% | $-0.30 | $619M |
| September 30, 2025 | $3.7B | 0.3% | $-0.11 | $658M |
| June 30, 2025 | $3.6B | −5.7% | $0.00 | $167M |
| March 31, 2025 | $3.2B | −11.2% | $-2.55 | $493M |
| December 31, 2024 | $3.5B | −8.1% | $-0.43 | $342M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $3.86B: Claude 35%, Gemini 60%, Mistral 40%
- Diluted earnings per share are above zero: Claude 30%, Gemini 15%, Mistral 30%
- Free cash flow for the quarter is at least $0.62B: Claude 45%, Gemini 75%, Mistral 55%
10 ledger entries and 33 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.